Clinical trial · Observational
HCC Staging Modified by Tumor Micronecrosis
Optimizing Hepatocellular Carcinoma Disease Staging Systems by Incorporating Tumor Micronecrosis: A Multi-institutional Retrospective Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Tumor micronecrosis is a pathological feature that reflects malignant biological behavior in hepatocellular carcinoma (HCC). This study aimed to evaluate the prognostic significance of tumor micronecrosis based on the current BCLC and TNM staging systems, and futher improve the performance of the staging models by establishing modified new staging models including tumor micronecrosis.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| tumor micronecrosis | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- micronecrosis(+) group
- description
- Hepatocellular patients with tumor micronecrosis.
- interventionNames
- Behavioral: tumor micronecrosis
- label
- micronecrosis(-) group
- description
- Hepatocellular patients without tumor micronecrosis.
Primary outcomes (1)
- measure
- Overall survival
- timeFrame
- from date after liver resection until death or last follow-up, whichever came first, assessed up to 72 months
- description
- the number of months from the date of surgery to the date of the last follow-up visit or time of death.
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * primary and histologically confirmed HCCs * patients who underwent curative liver resection Exclusion Criteria: * simultaneous presence of other tumors * patients who had received preoperative antitumor therapies * no available surgical specimens for evaluating micronecrosis status * gross tumor necrosis and Nscore = 3
References
Publications (0)
Data not yet available